JP2025515076A5 - - Google Patents

Info

Publication number
JP2025515076A5
JP2025515076A5 JP2024564870A JP2024564870A JP2025515076A5 JP 2025515076 A5 JP2025515076 A5 JP 2025515076A5 JP 2024564870 A JP2024564870 A JP 2024564870A JP 2024564870 A JP2024564870 A JP 2024564870A JP 2025515076 A5 JP2025515076 A5 JP 2025515076A5
Authority
JP
Japan
Prior art keywords
composition according
antibody
subject
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024564870A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025515076A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/020944 external-priority patent/WO2023215443A1/en
Publication of JP2025515076A publication Critical patent/JP2025515076A/ja
Publication of JP2025515076A5 publication Critical patent/JP2025515076A5/ja
Pending legal-status Critical Current

Links

JP2024564870A 2022-05-04 2023-05-04 視神経脊髄炎スペクトラム障害の治療のための組成物及び方法 Pending JP2025515076A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263338410P 2022-05-04 2022-05-04
US63/338,410 2022-05-04
PCT/US2023/020944 WO2023215443A1 (en) 2022-05-04 2023-05-04 Compositions and methods for the treatment of neuromyelitis optica spectrum disorder

Publications (2)

Publication Number Publication Date
JP2025515076A JP2025515076A (ja) 2025-05-13
JP2025515076A5 true JP2025515076A5 (cg-RX-API-DMAC7.html) 2026-05-12

Family

ID=88647020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024564870A Pending JP2025515076A (ja) 2022-05-04 2023-05-04 視神経脊髄炎スペクトラム障害の治療のための組成物及び方法

Country Status (5)

Country Link
US (1) US20260022164A1 (cg-RX-API-DMAC7.html)
EP (1) EP4519312A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025515076A (cg-RX-API-DMAC7.html)
CA (1) CA3251727A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023215443A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3161271A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Anti-c5 antibody for the treatment of neuromyelitis optica spectrum disorder
WO2025221479A1 (en) * 2024-04-16 2025-10-23 Alexion Pharmaceuticals, Inc. Biomarkers for monitoring effective treatment of neuromyelitis optica spectrum disorder (nmosd) with complement component c5 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201791366A1 (ru) * 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
US20200095307A1 (en) * 2018-09-21 2020-03-26 Alexion Pharmaceuticals, Inc. Compositions and methods for the treatment of neuromyelitis optica
CA3161271A1 (en) * 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Anti-c5 antibody for the treatment of neuromyelitis optica spectrum disorder

Similar Documents

Publication Publication Date Title
JP2023517236A5 (cg-RX-API-DMAC7.html)
AU2017325240B9 (en) Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X
JP7293122B2 (ja) 補体が媒介する疾患および障害を処置するための方法
US20200079871A1 (en) Treatment for multiple myeloma (mm)
JP2023533030A5 (cg-RX-API-DMAC7.html)
JP2020535149A5 (cg-RX-API-DMAC7.html)
JP2022536469A5 (cg-RX-API-DMAC7.html)
JP2022524204A (ja) 自己抗体介在性自己免疫疾患の処置のための、抗cd38抗体及びその医薬組成物
WO2018220040A1 (en) Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
AU2020382850A1 (en) Type I interferon inhibition in systemic lupus erythematosus
AU2023375340A1 (en) Methods for the treatment of cardiovascular disease
JP2023504209A5 (cg-RX-API-DMAC7.html)
JP2022520107A5 (cg-RX-API-DMAC7.html)
JP2023546503A5 (cg-RX-API-DMAC7.html)
JP2023510854A5 (cg-RX-API-DMAC7.html)
JP2022514561A5 (cg-RX-API-DMAC7.html)
JP2018533588A (ja) 治療パラダイム
JP2024540294A5 (cg-RX-API-DMAC7.html)
JP2021522241A5 (cg-RX-API-DMAC7.html)
JP2023546504A5 (cg-RX-API-DMAC7.html)
JP2023527059A5 (cg-RX-API-DMAC7.html)
JP2023506779A5 (cg-RX-API-DMAC7.html)
WO2025045766A1 (en) Compositions comprising humanized anti-cd40 antibodies and methods for treating rheumatoid arthritis using the same
JP2024526742A5 (cg-RX-API-DMAC7.html)
Léger A review of the medical management of chronic inflammatory demyelinating polyradiculoneuropathy